Search clinical trials for: CD30.CAR-T

Total 17519 results

Medical College of Wisconsin

Not yet recruiting

Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma

Multiple Myeloma
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study

T-lymphoblastic Lymphoma | T-ALL

China
Xuzhou Medical University
Yake Biotechnology Ltd.

Recruiting

Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple Myeloma (CAR-T)

Multiple Myeloma

China
Shenzhen Geno-Immune Medical Institute
The Second Affiliated Hospital of Hainan Medical University

Recruiting

Universal CAR-T Cells Targeting Multiple Myeloma

Multiple Myeloma in Remission

China
Xuzhou Medical University

Recruiting

Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM)

Multiple Myeloma

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

CAR-T for r/r Malignant Tumors in Children

Child, Only | Malignant Tumor | CAR-T

China
Jian-Kun Hu

Recruiting

Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART)

Metastases, Neoplasm | Neoplasm Seeding | Neoplasm, Stomach

China
Shanghai East Hospital
Bio4T2 LLC

Active, not recruiting

A Clinical Study to Evaluate B4T2-001 CAR T Cells in the Treatment of Advanced Solid Tumors

Advanced Solid Tumor

China
University of Pennsylvania

Terminated

CD19 Redirected Autologous T Cells for Hodgkin Lymphoma

Hodgkin Lymphoma With no Available Curative Treatment Options Who Have a Limited Prognosis

United States
YuLi

Unknown

Dual Target CAR-T Cells in B-cell Lymphoma (CAR-T)

Lymphoma, B-Cell | Refractory Lymphoma | Relapse/Recurrence | Dual-target CAR-T Cells

China
Kai Lin Xu; Jun Nian Zheng
iCarTAB BioMed Inc.; Huaian first people's hospital

Unknown

Humanized CAR-T Therapy for Treatment of B Cell Malignancy

Leukemia, Lymphocytic, Chronic, B-Cell

China
Miltenyi Biomedicine GmbH
ICON plc

Active, not recruiting

Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1)

B-cell Non Hodgkin Lymphoma

Germany
Shenzhen Geno-Immune Medical Institute

Recruiting

NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL

T-Cell Acute Lymphoblastic Leukemia

China
The Affiliated Hospital of Qingdao University

Not yet recruiting

Safety, Efficacy and Pharmacokinetics of XKDCT023 in DLBCL

Diffuse Large B Cell Lymphoma
Poseida Therapeutics, Inc.

Recruiting

P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors

Renal Cell Carcinoma | Breast Cancer | Nasopharyngeal Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma

United States
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome

Autoimmune Diseases | Sjogren's Syndrome

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus

Autoimmune Diseases | Systemic Lupus Erythematosus

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL

B-Cell Acute Lymphoblastic Leukemia, Adult

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Lymphoma, B-Cell | Leukemia, B-cell

China
Shenzhen Geno-Immune Medical Institute
Shenzhen Children's Hospital

Recruiting

4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma

Neuroblastoma

China
Fuda Cancer Hospital, Guangzhou

Withdrawn

Chimeric Antigen Receptor-Modified T Cells for Breast Cancer

Breast Cancer

China
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

Refractory Acute Lymphoblastic Leukemia | Philadelphia-Negative ALL | Philadelphia-Positive ALL | Refractory Acute Lymphoblastic Leukemia (ALL) | Relapsed ALL, Adult | Refractory Acute Lymphoid Leukemia in Relapse

United States
920th Hospital of Joint Logistics Support Force...
Gracell Biotechnology Shanghai Co., Ltd.; Kunming Hope of Health Hospital

Recruiting

CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed or Refractory B-cell Non-hodgkin Lymphoma

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma

Autoimmune Diseases | Scleroderma

China
Poseida Therapeutics, Inc.
Roche-Genentech

Recruiting

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (MM)

Multiple Myeloma

United States
National Taiwan University Hospital

Not yet recruiting

CD19 CAR T Cells in Children and Adults With Relapsed or Refractory CD19 Positive B Cell Malignancies

Relapsed/Refractory B-Cell Malignancies
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL

B-Cell Acute Lymphoblastic Leukemia, Adult

China
Chongqing Precision Biotech Co., Ltd

Recruiting

CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Lymphoma, B-Cell | Leukemia, B-cell

China
Shenzhen Geno-Immune Medical Institute
The Seventh Affiliated Hospital of Sun Yat-sen University; Shenzhen Children... and other collaborators

Recruiting

4SCAR-CD44v6 T Cell Therapy Targeting Cancer

Cancers Which Are CD44v6 Positive

China
Nanjing Legend Biotech Co.
Janssen Research & Development, LLC

Recruiting

A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma (CARTIFAN-1)

Multiple Myeloma

China
Poseida Therapeutics, Inc.

Active, not recruiting

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Neoplasms | Neoplasms by Histologic Type | Urogenital Neoplasms | Neoplasms by Site | Genital Neoplasms, Male | Prostatic Neoplasms | Adenoid Cystic Carcinoma | Mucoepidermoid Carcinoma | Prostate Cancer | Prostatic Neoplasms, Castration-Resistant | Metastatic Castration-resistant Prostate Cancer | Neoplasms... and other conditions

United States
Poseida Therapeutics, Inc.
California Institute for Regenerative Medicine (CIRM)

Terminated

P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

Multiple Myeloma

United States
Beijing Boren Hospital
Nanjing Legend Biotech Co.

Terminated

LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor

T-cell Leukemia | T Cell Lymphoma

China
The First Affiliated Hospital with Nanjing Medical...
Nanjing Legend Biotechnology Co. The First Affiliated Hospital of USTC west...

Terminated

LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma

CD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia)

China
Second Affiliated Hospital, School of Medicine,...

Completed

Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma

Transformed Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B-cell Lymphoma | Primary Mediastinal Large B-cell Lymphoma

China
Wuhan Union Hospital, China
Wuhan Bio-Raid Biotechnology Co., Ltd.

Unknown

Safety and Efficacy of Anti-CD123 CAR-T Therapy in Patients With Refractory/ Relapsed CD123+ Acute Myeloid Leukemia.

CD123+ Acute Myeloid Leukemia

China
First Affiliated Hospital of Harbin Medical University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Unknown

Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.

Pancreatic Cancer | CAR

China
Kai Lin Xu; Jun Nian Zheng
iCarTAB BioMed Inc.

Unknown

CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies

Recurrent or Refractory B Cell Malignancy

China
Peking University
University of Florida

Unknown

Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas (4SCAR19273)

B-cell Lymphomas

China
Beijing Tiantan Hospital
Tasly Pharmaceutical Group Co., Ltd; Beijing Neurosurgical Institute

Recruiting

Tris-CAR-T Cell Therapy for Recurrent Glioblastoma

Recurrent Glioblastoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou Anjie Biomedical Technology Co., Ltd.

Completed

PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer

Advanced Breast Cancer | Breast Neoplasm Malignant Female

China
Shanghai GeneChem Co., Ltd.
Shanghai Cancer Hospital, China

Unknown

A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy

Carcinoma, Hepatocellular | Colorectal Cancer Metastatic | Pancreatic Cancer Metastatic

China
Seattle Children's Hospital

Active, not recruiting

Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia

CD 19+ Acute Leukemia

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Withdrawn

CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA)

Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma

United States
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

Acute Lymphoblastic Leukemia, in Relapse | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory | Acute Lymphocytic Leukaemia Refractory

China
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd; Suzhou Hongci Hematology...

Recruiting

Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell | Autologous Stem Cell Transplantation

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia | CAR

China
Shenzhen BinDeBio Ltd.
Henan Provincial People's Hospital

Recruiting

Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies

Glioma | Gastric Cancer | Hepatoma | Esophagus Cancer

China
Peking Union Medical College Hospital
Cellular Biomedicine Group Ltd.

Completed

A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects

B-cell Non-Hodgkin Lymphoma

China
University of Pennsylvania

Completed

Umbilical Cord Blood Transplant for Hematological Malignancies (UCB)

Multiple Myeloma | AML | MDS | NHL | CML | Hodgkin's Disease | ALL

United States

Search clinical trials for: CD30.CAR-T

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations